Ovarian Cancer – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of ovarian cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of ovarian cancer for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

Clarivate Epidemiology’s ovarian cancer forecast will answer the following questions:

  • Of all people diagnosed with ovarian cancer, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ovarian cancer over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 78 ovarian cancer patient populations, including the following:

  • Diagnosed incident cases.
  • Diagnosed prevalent cases.
  • Diagnosed incident cases by stage.
  • Diagnosed incident cases by BRCA mutation.
  • Diagnosed early-stage DTP by drug treatment.
  • Diagnosed advanced-stage first-line DTP by drug treatment.
  • Diagnosed second-line DTP by drug treatment.
  • Diagnosed third-line DTP by drug treatment.
  • Diagnosed fourth and subsequent lines in the drug-treatment subpopulation(s).
  • Diagnosed prevalent cases by drug-treatment potential.

Note: Coverage may vary by country.

launch Related Market Assessment Reports